Power3 Medical files patent application for blood-based test for ALS

By Lisa Kerner

Erie, Pa., May 3 - Power3 Medical Products, Inc., in conjunction with three Houston-area research institutions, filed an application with the U.S. Patent and Trademark Office for its first generic, blood-based diagnostic test for neuromuscular disorders, including Amyotropic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and Parkinson's Disease.

Using a blood sample, the test separates the proteins present and analyzes a panel of protein biomarkers using proteomic techniques. The test then determines if a patient has a neuromuscular disease based on the quantity of the biomarkers and biostatistical analysis.

The company filed a provisional patent application on April 24 for a test identifying which patients with Chronic Myelogenous Leukemia (CML) are resistant to, or could build resistance to, imatinib mesylate (Gleevec), the leading drug used to treat CML.

Power3 said it has 20 patents or patents pending for its work developing testing methods and technologies for neurodegenerative diseases including ALS, Alzheimer's, Parkinson's and breast cancer, as well as drug resistance.

Power3 is a proteomics company based in The Woodlands, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.